Inotiv reported fourth-quarter fiscal 2025 revenue of $138.1 million, up 5.9% year over year, and full-year revenue of $513.0 million, up 4.5%. Operating losses narrowed sharply to $6.8 million in the quarter and $30.9 million for the year, while adjusted EBITDA improved to $11.8 million in Q4 and $34.0 million for FY 2025. The Discovery & Safety Assessment segment did the heavy lifting, rising 15.7% in Q4 with a 1.08x book-to-bill and backlog up to $138.2 million. Research Models & Services grew modestly, with full-year gains tied to increased non-human primate product and service revenue. The company sold two U.S. properties to reduce debt, engaged Perella Weinberg Partners to explore refinancing, and disclosed an August cybersecurity incident with systems restored and impact still being assessed.
The operational trajectory points up, but the balance sheet flashes red. Cash sits at $21.7 million against $402 million of debt reclassified as current, and interest expense climbed to $56.6 million for the year. For sponsors relying on Inotiv for IND-enabling work and specialized bioanalytics, the near-term question is whether improving demand and mix shift can outrun refinancing risk. Execution on debt solutions will determine if margin gains in DSA translate into durable capacity and service continuity for clients.
This matters now because preclinical throughput is again a gating factor for pipeline timelines. DSA growth was driven by biotherapeutic analysis, general tox, and surgical services, with new business at the Rockville site signaling rising demand from biologics and advanced modalities. RMS was buoyed by better availability and economics for non-human primates, a pressure point that has delayed safety packages across the industry. Sponsors facing 2026–2027 launch windows cannot afford upstream slippage. Medical Affairs teams should note the intensifying reliance on complex bioanalytical methods that not only support regulatory filings but also form the foundation for post-approval evidence generation, immunogenicity monitoring, and label expansion strategies.
The cyber incident elevates a different risk vector. As FDA and global regulators tighten expectations for data integrity and vendor oversight, sponsors will scrutinize third-party security posture alongside GLP compliance. The incident arrives amid a broader trend of healthcare and life sciences cyberattacks, shifting procurement from price-and-capacity decisions to a triad of capacity, quality, and resilience. CROs that can demonstrate credentialed cybersecurity and transparent remediation may convert this into a competitive advantage.
More broadly, Inotiv’s print offers a microcosm of a preclinical CRO market healing after the biotech funding trough. A book-to-bill above one and a growing backlog suggest program reactivation, especially in biologics and cell and gene therapy, where bioanalytics and surgical capabilities are bottlenecks. Yet smaller, debt-laden platforms face a higher cost of capital just as they need to invest in capacity, digital infrastructure, and compliance. That combination increases the likelihood of continued refinancing, asset sales, or consolidation, with sponsors reassessing vendor concentration risk and building dual-sourcing strategies across DSA and research models.
For Commercial and Medical leaders, the practical takeaway is to pressure-test vendor resilience while exploiting the current opening to secure preferred capacity and assay development slots. The strategic watch items are straightforward: does Inotiv close a refinancing that de-risks 2026 maturities, do DSA net awards continue to outpace revenue conversion, and does the cyber remediation satisfy sponsor and regulatory expectations? If the company stabilizes its capital structure while leaning further into higher-margin DSA, it could emerge as a more focused preclinical partner; if not, will programs be forced to migrate midstream, reshaping sponsor timelines and competitive launch sequences?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
